Zhifei - Beijing R&D center expands to build innovative product incubation center

Release time:2023-03-28  |  Click rate:

Based on the original technology platform of the R&D center in Beijing, Zhifei once again expands its R&D layout and builds an innovative product incubation center to focus on cutting-edge technologies in the vaccine industry, carries out original technology innovation, overcomes technical difficulties in the industry, and provide underlying technical support for the R&D of more innovative products.

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., the wholly-owned subsidiary of Zhifei, started construction of the innovative product incubation center in October 2022, with a construction area of more than 7,000 ㎡ and a planned investment of 100 million RMB. The incubation center is planned to include a nucleic acid vaccine R&D technology platform, novel antigen screening and synthesis technology platform, novel adjuvant R&D technology platform, vaccine delivery system technology platform, structure and quality technology platform, and develop recombinant protein, recombinant adenovirus vector, outer membrane vesicles (OMV), messenger RNA (mRNA) and other innovative vaccine technologies, as well as cultivating innovative talent team. Currently, the incubation center has nearly 70 professional staff of and is expected to complete construction and put into use in April this year.

Previously, the Beijing R&D Center has built a high standard R&D technology platform covering more than 13,000 ㎡, including five innovative vaccine technology platforms, i.e., polysaccharide and conjugate, recombinant protein, viral, recombinant vector and bacterial platforms, equipped with advanced vaccine trial production equipment and quality analysis instruments at home and abroad,and process international level research, laboratory test and pilot test environment. Currently, 3 new vaccine candidates have completed clinical trials and are applying for New Drug Application, another 8 new vaccine candidates have obtained clinical trial approval and are carrying out clinical researches, and a variety of new candidates are in the pre-clinical research stage.

The completion of the incubation center will further enhance the R&D strength of Zhifei, strengthen the original technology innovation capability, incubate more innovative new vaccine candidates, and is expected to develop 5-10 new vaccine candidates to enter the clinical research stage or transformation stage in the next 10 years, effectively improve the response capability of outbreak of infectious diseases and new infectious diseases at home and abroad, and protect human health!